Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
Phase 2
- Conditions
- Liver CancerHepatoCellular Carcinoma
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Ivy Life Sciences, Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT03592706
- Locations
- 🇨🇳
Tri Service General Hospital, Taipei, Taiwan
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
Phase 1
Completed
- Conditions
- NSCLC Stage IVHepatocellular Carcinoma by BCLC StageLung CancerLiver CancerNSCLC Stage IIIB
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Ivy Life Sciences, Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT03515252
A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Ivy Life Sciences, Co., Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT03499834
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Tri Service General Hospital, Taipei, Taiwan
News
No news found